Delamanid

Drug Profile

Delamanid

Alternative Names: Deltyba; OPC-67683; UNII-8OOT6M1PC7

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Otsuka Pharmaceutical
  • Developer Mylan; Otsuka Pharmaceutical
  • Class 2 ring heterocyclic compounds; Antituberculars; Nitroimidazoles; Oxazoles; Phenyl ethers; Piperidines; Small molecules
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Tuberculosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Tuberculosis

Most Recent Events

  • 24 Aug 2017 Mylan agree to commercialise delamanid in South Africa and India for Tuberculosis
  • 24 Aug 2017 Preregistration for Tuberculosis in South Africa (PO) before August 2017
  • 24 Aug 2017 Registered for Tuberculosis in Hong Kong (PO) before August 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top